Premium
The alpha‐globin genotype does not influence sickle cell disease severity in a retrospective cross‐validation study of the pediatric severity score
Author(s) -
Joly Philippe,
Pondarré Corinne,
Bardel Claire,
Francina Alain,
Martin Cyril
Publication year - 2012
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2011.01705.x
Subject(s) - genotype , medicine , alpha globulin , disease , retrospective cohort study , sickle cell anemia , alpha (finance) , genetics , gene , biology , surgery , construct validity , patient satisfaction
Abstract To validate the recently proposed pediatric severity score (PSS) for sickle cell disease (SCD), we retrospectively assembled clinical data from a cohort of 122 patients with SCD (105 S/S or S/β 0 ‐thal. and 17 S/C) followed up for at least 2 years. Besides age and α‐ and β‐globin genotypes, four new parameters were also tested against the PSS: duration of data assembly, neonatal screening, use of transcranial Doppler ultrasound to prevent vasculopathies and β‐globin gene cluster haplotype. Once again, the PSS clearly differentiated patients by their β‐globin genotype ( P = 0.004) but not by their age during data assembly ( P = 0.159). But, surprisingly, alpha‐gene deletions were not associated with a lower PSS ( P = 0.604), possibly reflecting the opposite effects of α‐thalassemia on global SCD severity. As for the newly tested parameters, the PSS appeared not to be influenced by the duration of data assembly ( P = 0.071) and neonatal screening ( P = 0.678) but rather by the introduction of transcranial Doppler ultrasound ( P = 0.006). Moreover, the Senegal haplotype at the homozygous state may be associated with a lower PSS. Methodologically, our data globally confirm the usefulness of the PSS to identify major etiological factors of SCD gravity. Nevertheless, the score is surely underestimated for patients who have been switched to a chronic therapy before the main SCD complications. Biologically, our study questions about the exact influence of α‐thalassemia on global SCD severity.